Download PDF
Ernährung & Medizin 2006; 21(4): 163-172
DOI: 10.1055/s-2006-957083
Originalia und Übersichten
© Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Strukturierte Adipositastherapie

A structured therapy of obesityE. Siewert1 , E. Purucker2
  • 1Medizinische Klinik III, Universitätsklinikum Aachen
  • 2Klinikum Niederrhein, Evangelisches Krankenhaus Dinslaken
Further Information

Publication History

Publication Date:
04 January 2007 (online)

    Permissions and Reprints

Zusammenfassung

Die Adipositas nimmt weltweit rapide zu. Therapieempfehlungen wurden in der aktuellen „Evidenzbasierten Leitlinie zur Prävention und Therapie der Adipositas” gegeben: Die Basistherapie umfasst drei miteinander kombinierte Prinzipien: die Verhaltens-, Bewegungs- und Ernährungstherapie. Die Ernährungstherapie wird in vier Stufen zunehmend reduzierter Energiezufuhr unterteilt. Eine medikamentöse Therapie durch Orlistat, Sibutramin oder möglicherweise Rimonabant ist als ergänzende Maßnahme unter bestimmten Voraussetzungen und Beachtung von Kontraindikationen über begrenzte Zeiträume möglich. Chirurgische Interventionen kommen für Personen mit einer höhergradigen Adipositas (BMI > 35 - 40 kg/m2) in Betracht, die mit konservativen Maßnahmen keine befriedigende Gewichtsreduktion erzielen konnten. Bei allen Therapieformen ist eine langfristige Begleitung durch verschiedene Fachdisziplinen und unter Beachtung individueller Besonderheiten erforderlich. Eine Ernährungsumstellung ist wesentliche Voraussetzung jedes dauerhaft erfolgreichen Gewichtsmanagements, und der vor allem in den ersten Monaten zu erreichender Gewichtsabnahme sollte sich immer eine Phase der Gewichtsstabilisierung anschließen. Schon aufgrund von Komorbiditäten und Folgekosten ist eine Anerkennung der Adipositas als Erkrankung im Sinne des deutschen Sozialgesetzbuches überfällig. Dem Erreichen einer Bündelung aller Kräfte der Berufsgruppen und Kostenträger im Gesundheitssystem sowie in der Gesellschaft hinsichtlich des Erreichens realistischer Ziele bei der Prävention der Adipositas sollte auch aus langfristigen gesundheitsökonomischen Gesichtspunkten alle nur mögliche Aufmerksamkeit zukommen.

Summary

Obesity is growing rapidly the world over. The recently published German „Evidence-based Guideline for Prevention and Therapy of Obesity” specifies three combined principles of management, namely behavioural therapy, kinesitherapy and nutritional therapy. The latter indicates four phases of reducing uptake of energy for limited periods, possibly supplemented by drugs such as Orlistat, Sibutramin and/or Rimonabant, strictly observing contraindications. If conservative treatment does not achieve desirable results, persons afflicted by high-grade obesity (body-mass index 35 - 40) without adequate weight reduction may need surgical intervention. All kinds of therapy will require long-term professional control. An essential component of successful weight management is a change of diets, with a subsequent phase of weight stabilisation. Approving obesity as a disease in the sense of German social legislation is overdue, in particular in view of a possible comorbidity and of potential sequential costs. All professional groups and cost units in the public health system ought to co-operate in the objective of achieving realistic results in combating obesity under health-economic aspects.

Schlüsselwörter

Adipositas - Gewichtsmanagement - evidenzbasierte Leitlinie - Ernährungstherapie - Reduktionskost - low-carb diet - Bewegungstherapie - Verhaltenstherapie - Antiadiposita - Bariatrische Chirurgie

Key words

Obesity - weight management - evidence-based guidelines - nutritional therapy - weight-reducing diet - low-carb diet - kinesitherapy - behaviour therapy - antiadiposita - bariatric surgery

Literatur

  • 1 Adams K F, Schatzkin A, Harris T B. et al . Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.  N Engl J Med. 2006;  355 763-778
    CrossrefPubMedGoogle Scholar
  • 2 Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.  Diabet Med. 1998;  15 539-553
    CrossrefPubMedGoogle Scholar
  • 3 Andersen R E, Wadden T A, Bartlett S J. et al . Effects of lifestyle activity vs structured aerobic exercise in obese women: a randomized trial.  JAMA. 1999;  281 335-340
    CrossrefPubMedGoogle Scholar
  • 4 Ash S, Reeves M M, Yeo S. et al . Effect of intensive dietetic interventions on weight and glycaemic control in overweight men with Type II diabetes: a randomised trial.  Int J Obes Relat Metab Disord. 2003;  27 797-802
    CrossrefPubMedGoogle Scholar
  • 5 Astrup A, Grunwald G K, Melanson E L, Saris W H, Hill J O. The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies.  Int J Obes Relat Metab Disord. 2000;  24 1545-1552
    CrossrefPubMedGoogle Scholar
  • 6 Balkau B, Vierron E, Vernay M. et al . The impact of 3-year changes in lifestyle habits on metabolic syndrome parameters: the D.E.S.I.R. study.  Eur J Cardiovasc Prev Rehabil. 2006;  13 334-340
    CrossrefPubMedGoogle Scholar
  • 7 Bleichener F, Bönner G, Nord-Ruediger D. et al .Leitlinie zur Adipositastherapie in Reha-Kliniken. Auflage 2003. www.adipositas-gesellschaft.de
    Google Scholar
  • 8 Chan J M, Rimm E B, Colditz G A, Stampfer M J, Willett W C. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.  Diabetes Care. 1994;  17 961-969
    CrossrefPubMedGoogle Scholar
  • 9 Colditz G A, Willett W C, Rotnitzky A, Manson J E. Weight gain as a risk factor for clinical diabetes mellitus in women.  Ann Intern Med. 1995;  122 481-486
    PubMedGoogle Scholar
  • 10 De Petrocellis L, Cascio M G, Di Marzo V. The endocannabinoid system: a general view and latest additions.  Br J Pharmacol. 2004;  141 765-774
    CrossrefPubMedGoogle Scholar
  • 11 DeFronzo R A, Ratner R E, Han J. et al . Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.  Diabetes Care. 2005;  28 1092-1100
    CrossrefPubMedGoogle Scholar
  • 12 Despres J P, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.  N Engl J Med. 2005;  353 2121-2134
    CrossrefPubMedGoogle Scholar
  • 13 Deutsche Gesellschaft für Ernährung. DGE-Beratunsstandards Auflage 2003. www.dge.de
    Google Scholar
  • 14 Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation.  Nat Rev Drug Discov. 2004;  3 771-784
    CrossrefPubMedGoogle Scholar
  • 15 Ditschuneit H H, Flechtner-Mors M, Johnson T D, Adler G. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients.  Am J Clin Nutr. 1999;  69 198-204
    PubMedGoogle Scholar
  • 16 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 285: 2486-2497
    Google Scholar
  • 17 Fontaine K R, Redden D T, Wang C, Westfall A O, Allison D B. Years of life lost due to obesity.  JAMA. 2003;  289 187-193
    CrossrefPubMedGoogle Scholar
  • 18 Foster G D, Wyatt H R, Hill J O. et al . A randomized trial of a low-carbohydrate diet for obesity.  N Engl J Med. 2003;  348 2082-2090
    CrossrefPubMedGoogle Scholar
  • 19 Hauner H, Wechsler J, Kluthe R. et al . Qualitätskriterien für ambulante Adipositasprogramme.  Akt Ernaehr Med. 2000;  25 163-165
    PubMedGoogle Scholar
  • 20 Hauner H. Evidence based therapy of obesity.  Internist (Berl). 2006;  47 159-170
    CrossrefPubMedGoogle Scholar
  • 21 Hauner H, Buchholz G, Hamann A. et al .Evidenzbasierte Leitlinie - Prävention und Therapie der Adipositas. www.adipositas-gesellschaft.de. 2006
    Google Scholar
  • 22 Husemann B. Open-surgery management of morbid obesity: old experience-new techniques.  Langenbecks Arch Surg. 2003;  388 385-391
    CrossrefPubMedGoogle Scholar
  • 23 International-Diabetes-Federation: The IDF a consensus worldwide definition of the metabolic syndrome. 2005. www.idf.org
    Google Scholar
  • 24 Ioannides-Demos L L, Proietto J, McNeil J J. Pharmacotherapy for obesity.  Drugs. 2005;  65 1391-1418
    CrossrefPubMedGoogle Scholar
  • 25 Jee S H, Sull J W, Park J. et al . Body-mass index and mortality in Korean men and women.  N Engl J Med. 2006;  355 779-787
    CrossrefPubMedGoogle Scholar
  • 26 Jeffery R W, Wing R R, Sherwood N E, Tate D F. Physical activity and weight loss: does prescribing higher physical activity goals improve outcome?.  Am J Clin Nutr. 2003;  78 684-689
    PubMedGoogle Scholar
  • 27 Kendall D M, Riddle M C, Rosenstock J. et al . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.  Diabetes Care. 2005;  28 1083-1091
    CrossrefPubMedGoogle Scholar
  • 28 Knowler W C, Barrett-Connor E, Fowler S E. et al . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
    CrossrefPubMedGoogle Scholar
  • 29 Koh-Banerjee P, Chu N F, Spiegelman D. et al . Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men.  Am J Clin Nutr. 2003;  78 719-727
    PubMedGoogle Scholar
  • 30 Manini T M, Everhart J E, Patel K V. et al . Daily activity energy expenditure and mortality among older adults.  JAMA. 2006;  296 171-179
    CrossrefPubMedGoogle Scholar
  • 31 McTigue K, Larson J C, Valoski A. et al . Mortality and cardiac and vascular outcomes in extremely obese women.  JAMA. 2006;  296 79-86
    CrossrefPubMedGoogle Scholar
  • 32 Mensink G B, Lampert T, Bergmann E. Overweight and obesity in Germany 1984 - 2003.  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005;  48 1348-1356
    CrossrefPubMedGoogle Scholar
  • 33 Noakes M, Foster P R, Keogh J B, Clifton P M. Meal replacements are as effective as structured weight-loss diets for treating obesity in adults with features of metabolic syndrome.  J Nutr. 2004;  134 1894-1899
    PubMedGoogle Scholar
  • 34 Olshansky S J, Passaro D J, Hershow R C. et al . A potential decline in life expectancy in the United States in the 21st century.  N Engl J Med. 2005;  352 1138-1145
    CrossrefPubMedGoogle Scholar
  • 35 Padwal R, Li S K, Lau D C. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004:CD004094
    Google Scholar
  • 36 Pan X R, Li G W, Hu Y H. et al . Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.  Diabetes Care. 1997;  20 537-544
    CrossrefPubMedGoogle Scholar
  • 37 Pavlou K N, Krey S, Steffee W P. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects.  Am J Clin Nutr. 1989;  49 1115-1123
    PubMedGoogle Scholar
  • 38 Pi-Sunyer F X. Medical hazards of obesity.  Ann Intern Med. 1993;  119 655-660
    PubMedGoogle Scholar
  • 39 Pi-Sunyer F X, Aronne L J, Heshmati H M, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.  JAMA. 2006;  295 761-775
    CrossrefPubMedGoogle Scholar
  • 40 Samaha F F, Iqbal N, Seshadri P. et al . A low-carbohydrate as compared with a low-fat diet in severe obesity.  N Engl J Med. 2003;  348 2074-2081
    CrossrefPubMedGoogle Scholar
  • 41 Schnee D M, Zaiken K, McCloskey W W. An update on the pharmacological treatment of obesity.  Curr Med Res Opin. 2006;  22 1463-1474
    CrossrefPubMedGoogle Scholar
  • 42 Sjostrom L, Lindroos A K, Peltonen M ,. et al . Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.  N Engl J Med. 2004;  351 2683-2693
    CrossrefPubMedGoogle Scholar
  • 43 Torgerson J S, Hauptman J, Boldrin M N, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.  Diabetes Care. 2004;  27 155-161
    Google Scholar
  • 44 Toubro S, Astrup A. Randomised comparison of diets for maintaining obese subjects’ weight after major weight loss: ad lib, low fat, high carbohydrate diet v fixed energy intake.  BMJ. 1997;  314 29-34
    PubMedGoogle Scholar
  • 45 Tuomilehto J, Lindstrom J, Eriksson J G. et al . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
    CrossrefPubMedGoogle Scholar
  • 46 Van Gaal L F, Rissanen A M, Scheen A J, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.  Lancet. 2005;  365 1389-1397
    CrossrefPubMedGoogle Scholar
  • 47 Wadden T A, Berkowitz R I, Womble L G. et al . Randomized trial of lifestyle modification and pharmacotherapy for obesity.  N Engl J Med. 2005;  353 2111-2120
    Google Scholar
  • 48 Weintraub M, Sundaresan P R, Madan M. et al . Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.  Clin Pharmacol Ther. 1992;  51 586-594
    PubMedGoogle Scholar
  • 49 WHO: Technical Report Series 894. Genf; 2000
    Google Scholar
  • 50 Williams K V, Mullen M L, Kelley D E, Wing R R. The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes.  Diabetes Care. 1998;  21 2-8
    PubMedGoogle Scholar
  • 51 Wing R R, Tate D F, Gorin A A, Raynor H A, Fava J L. A self-regulation program for maintenance of weight loss.  N Engl J Med. 2006;  355 1563-1571
    CrossrefPubMedGoogle Scholar
  • 52 Yusuf S, Hawken S, Ounpuu S. et al . Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.  Lancet. 2004;  364 937-952
    CrossrefPubMedGoogle Scholar

Priv.-Doz. Dr. med. Elmar Siewert

Medizinische Klinik III

Universitätsklinikum Aachen

Pauwelsstr. 30

52074 Aachen

      >